Synmosa Biopharma Corp AI Stock Analysis
Synmosa Biopharma Corp (4114) AI Stock Analysis
Synmosa Biopharma Corp
(TPEx:4114)
The overall score is constrained by extremely weak technical momentum and poor cash flow generation, which are the most significant risk factors. While the balance sheet is healthy and valuation is reasonable, the stock is in a strong downtrend with an oversold RSI, and the company's cash conversion has deteriorated markedly. The stable dividend yield offers some support but does not offset the prevailing operational and technical headwinds.
Synmosa Biopharma Corp (4114) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 14.85B
- Dividend Yield
- 3.09%
- Average Volume (3M)
- 842.21K
- Price to Earnings (P/E)
- 17.4
- Beta (1Y)
- 0.29
- Revenue Growth
- 20.99%
- EPS Growth
- 5.70%
- Country
- TW
- Employees
- 495
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Synmosa Biopharma Corp Business Overview & Revenue Model
Company Description
Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to m...
Synmosa Biopharma Corp Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is strong with low leverage (D/E 0.29), but income growth has stalled (1.3% revenue growth) and cash flow has deteriorated sharply, with free cash flow collapsing 37%. The inability to convert profits into cash is a major concern.
Income Statement
58NeutralBalance Sheet
72PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.68B | 6.19B | 5.55B | 5.14B | 4.39B | 3.23B |
| Gross Profit | 2.72B | 2.54B | 2.40B | 2.12B | 1.83B | 1.29B |
| EBITDA | 1.03B | 1.12B | 1.06B | 1.01B | 1.10B | 507.92M |
| Net Income | 775.69M | 821.85M | 684.68M | 594.83M | 799.09M | 303.86M |
Balance Sheet | ||||||
| Total Assets | 15.28B | 13.99B | 12.30B | 11.73B | 11.20B | 10.32B |
| Cash, Cash Equivalents and Short-Term Investments | 2.78B | 2.93B | 1.89B | 1.65B | 1.42B | 993.13M |
| Total Debt | 3.36B | 2.52B | 2.55B | 2.44B | 3.37B | 3.46B |
| Total Liabilities | 5.41B | 3.89B | 3.91B | 3.63B | 4.55B | 4.22B |
| Stockholders Equity | 8.65B | 8.76B | 7.21B | 6.71B | 5.31B | 4.71B |
Cash Flow | ||||||
| Free Cash Flow | 150.99M | 130.44M | 510.97M | 242.16M | 445.92M | 312.74M |
| Operating Cash Flow | 355.79M | 411.57M | 780.62M | 511.93M | 630.25M | 454.86M |
| Investing Cash Flow | -1.14B | -663.53M | -336.80M | -717.87M | -69.33M | 73.33M |
| Financing Cash Flow | 345.94M | 964.20M | -187.55M | 37.24M | -347.94M | -297.57M |
Synmosa Biopharma Corp Peers Comparison
Overall Rating
TW:662070Outperform
TW:178957Neutral
TW:411452Neutral
TW:414747Neutral
TW:654740Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | TWD 20.42B | 64.32 | ― | 1.74% | ― | ― | |
| 57Neutral | TWD 15.54B | 891.40 | ― | 1.47% | -4.75% | -91.36% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | TWD 14.80B | 17.37 | ― | 3.09% | 20.99% | 5.70% | |
| 47Neutral | TWD 16.94B | -107.17 | ― | ― | 7.02% | 25.72% | |
| 40Underperform | TWD 15.39B | -411.69 | ― | ― | 44.37% | 78.11% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4114 | Synmosa Biopharma Corp | 27.45 | -1.43 | -4.94% | |
| TW:1789 | Scinopharm Taiwan, Ltd. | 19.70 | 2.69 | 15.82% | |
| TW:4147 | TaiMed Biologics Inc. | 64.30 | -2.60 | -3.89% | |
| TW:6547 | Medigen Vaccine Biologics Corp. | 46.85 | 9.70 | 26.11% | |
| TW:6589 | EirGenix, Inc. | 55.60 | -20.90 | -27.32% | |
| TW:6620 | Handa Pharmaceuticals Inc | 119.00 | 1.43 | 1.21% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
